Lyuba Varticovski, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 41, Room D305
- Bethesda, MD 20892-5505
- 240-760-6736
- varticol@mail.nih.gov
RESEARCH SUMMARY
Our laboratory pioneered the analysis of global chromatin landscape using DnaseI hypersensitive sites (sites in the entire mammalian genome that are accessible to interaction with regulatory elements at any time) in normal and cancer cells, and their changes in response to drugs and activation of nuclear receptors. We adapted this method to probe global chromatin modifications during differentiation of stem cells into osteogenic lineage, a process that requires glucocorticoids, in characterizing metastatic potential, and acquisition of drug resistance.
Areas of Expertise
Lyuba Varticovski, M.D.
Research
Publications
- Bibliography Link
- View Dr. Varticovski's PubMed Summary.
High Quality ATAC-Seq Data Recovered from Cryopreserved Breast Cell Lines and Tissue.
High Quality ATAC-Seq Data Recovered from Cryopreserved Breast Cell Lines and Tissue.
Prevalent glucocorticoid and androgen activity in US water sources
Targeted H3R26 deimination specifically facilitates estrogen receptor binding by modifying nucleosome structure
A quantitative high-throughput assay for detection of biologically active endocrine-disrupting chemicals in water
Biography
Lyuba Varticovski, M.D.
Dr. Varticovski was born in Siberia, Russia, where she completed undergraduate and first-year medical school. She received her M.D. degree from the University of Valle, Colombia. After a 2-year research fellowship with Max Wintrobe and James Kushner at the Univeristy of Utah and training in internal medicine at Albany Medical College, NY, she completed her fellowship in hematology and oncology at the New England Medical Center in Boston, MA. She joined the laboratory of Lewis C. Cantley in 1985 where she shared in the discovery and biochemistry of phosphatidylinositol 3-kinase (PI 3-Kinase). She held a clinical staff position in hematology and oncology at a Tufts University-affiliated hospital in Boston, MA, from 1989 to 2001. She studied the role of PI 3-kinase in protein-tyrosine kinase-mediated signal transduction, drug resistance and vesicular trafficking at Tufts Medical School where she rose to the rank of Associate Professor. Dr. Varticovski is board-certified in internal medicine and hematology and board-eligible in oncology. She is a member of the American Society for Hematology, American Society of Clinical Oncology and the American Association for Cancer Research.
In 2003, she joined the National Cancer Institute (NCI) in Bethesda, Maryland as a Staff Clinician and was subsequently promoted to Associate Scientist. At the NCI Center for Cancer Research, Dr. Varticovski has directed the Preclinical Models Strategy Team, Molecular Targeting Unit, Lung Cancer Stem Cell Core, and participated in clinical trials at the NIH Clinical Center for patients with drug-resistant tumors. She is currently a member of the Laboratory of Receptor Biology and Gene Expression, under the direction of Dr. Gordon Hager, where she focuses on genome-wide characterization of normal and cancer stem cells and their differentiation into osteogenic lineage.